UK Trials World's First Norovirus Vaccine to Ease NHS Burden

The Moderna-developed mRNA vaccine aims to prevent the highly contagious vomiting bug, currently causing significant strain on healthcare systems.

The trial involves 2,500 UK participants, with half receiving the vaccine and the other half a placebo.
Researchers hope the vaccine will demonstrate at least 65% efficacy in preventing norovirus.
Norovirus causes around 12,000 hospital admissions annually in the UK and is a major contributor to winter NHS pressures.
The trial is part of a 10-year partnership between the UK government and Moderna to advance life sciences.
If successful, the vaccine could be available on the NHS by 2026, potentially extending trials to children.